We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Highlights Its Innovative Diagnostic Products Revolutionizing Healthcare at MEDLAB Middle East

By LabMedica International staff writers
Posted on 25 Jan 2022

Randox Laboratories (Crumlin, UK) showcased the Vivalytic all-in-one molecular diagnostics solution and the Randox Discovery benchtop lab at MEDLAB Middle East which took place 24-27 January 2022 at the Dubai World Trade Centre. More...

The innovative platform Vivalytic developed by Randox in partnership with Bosch aims to change accessibility to molecular diagnostics. Using Randox-patented Biochip Array Technology, it is the easiest-to-use and most-comprehensive multiplex PCR platform on the market. It provides the broadest range of test options ever seen for an analyzer of its size, and also supports single-plex and low-plex testing, simplifying the processes for otherwise-complex laboratory test procedures. Depending on the test application, results will be delivered from 30 minutes. The Vivalytic is the perfect fit for any laboratory with numerous benefits to enhance testing capabilities.

Also on display at this year’s at MEDLAB Middle East was the Randox Discovery, an exciting and unique analyzer consolidating molecular and immunoassay workflows onto one compact benchtop platform. The COVID-19 diagnostic analyzer is the first to combine sample preparation techniques including extraction, PCR & Biochip Technology. Simple and easy to use, the intuitive user-interface guides the operator through the entire testing process. Built with the user and laboratory in mind, a single operator is all that is required to run up to three fully automated discovery platforms increasing operator walkaway time and ensuring rapid turnaround time of three hours to first batch results.

Related Links:
Randox Laboratories 


New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.